StockData

Shoulder Innovations vs Sanara MedTech

SI and SMTI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SI and SMTI compare

Shoulder Innovations is the larger company, worth 1.4 times as much as Sanara MedTech ($428M against $301M).

Shoulder Innovations grew revenue faster over the last twelve months (60.9% versus 13.0% for Sanara MedTech).

Sanara MedTech keeps more of each dollar of sales as profit, with a net margin of −29.2% compared with −58.3% at Shoulder Innovations.

Shoulder Innovations scores higher on the StockData Score (7 against 6 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSISMTI
Size and price
Market cap$428M$301M
Share price$20.56$32.73
Change, 1 year39.9%51.9%
Change, 5 years–14.2%
Beta (5Y)−0.521.43
Employees75108
StockData Score
Total score7 (better)6
Valuation score00
Growth score33
Performance score01 (better)
Health score4 (better)2
Dividend score00
Valuation
P/S7.1×2.7× (better)
P/B3.4× (better)37.9×
EV/EBITDA–30.4×
P/FCF–66.8×
FCF yield−11.0%1.5% (better)
Fair value$13.66$13.42
Margin of safety−50.5% (better)−144%
Growth
Revenue growth (TTM)60.9% (better)13.0%
Revenue growth, 5Y average–45.9%
Profitability
Gross margin77.3%93.0% (better)
Operating margin−58.5%7.7% (better)
Net margin−58.3%−29.2% (better)
FCF margin−78.4%4.1% (better)
Return on equity−152%−148% (better)
Return on invested capital–13.1%
Financial health
Debt / equity0.12 (better)5.85
Net debt / EBITDA–2.85
Interest coverage–1.2×
Current ratio10.71 (better)2.58
Altman Z-score8.83 (better)3.76
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.8%19.4%
Held by insiders40.0%14.9%
Insider net buying, 12 months−$5.3M–
Short interest, % of float5.7%5.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.